Minimal Residual Disease (MRD) detection is transforming oncology by enabling better monitoring of treatment response and early relapse detection. In this webinar, IntegraGen discusses the development of its tumor-informed MRD workflow, developed in partnership with Twist Bioscience. The integrated test combines high-quality sequencing, custom panels, and advanced bioinformatics.With insights from clinical studies and a focus on real-world implementation, this session will highlight how this partnership resulted in an integrated approach that supports pharma and clinical teams in bringing MRD testing into routine clinical practice.